Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 24

1.

Id1 expression in endothelial cells of the colon is required for normal response to injury.

Zhang N, Subbaramaiah K, Yantiss RK, Zhou XK, Chin Y, Scherl EJ, Bosworth BP, Benezra R, Dannenberg AJ.

Am J Pathol. 2015 Nov;185(11):2983-93. doi: 10.1016/j.ajpath.2015.07.005. Epub 2015 Sep 5.

PMID:
26348574
2.

Regulation of AKT signaling by Id1 controls t(8;21) leukemia initiation and progression.

Wang L, Man N, Sun XJ, Tan Y, Cao MG, Liu F, Hatlen M, Xu H, Huang G, Mattlin M, Mehta A, Rampersaud E, Benezra R, Nimer SD.

Blood. 2015 Jul 30;126(5):640-50. doi: 10.1182/blood-2015-03-635532. Epub 2015 Jun 17.

3.

Inhibitor of differentiation 4 (ID4) acts as an inhibitor of ID-1, -2 and -3 and promotes basic helix loop helix (bHLH) E47 DNA binding and transcriptional activity.

Sharma P, Chinaranagari S, Chaudhary J.

Biochimie. 2015 May;112:139-50. doi: 10.1016/j.biochi.2015.03.006. Epub 2015 Mar 13.

PMID:
25778840
4.

ID1 promotes breast cancer metastasis by S100A9 regulation.

Gumireddy K, Li A, Kossenkov AV, Cai KQ, Liu Q, Yan J, Xu H, Showe L, Zhang L, Huang Q.

Mol Cancer Res. 2014 Sep;12(9):1334-43. doi: 10.1158/1541-7786.MCR-14-0049. Epub 2014 Jun 19.

5.

ID proteins regulate diverse aspects of cancer progression and provide novel therapeutic opportunities.

Nair R, Teo WS, Mittal V, Swarbrick A.

Mol Ther. 2014 Aug;22(8):1407-15. doi: 10.1038/mt.2014.83. Epub 2014 May 14. Review.

6.

Small-molecule inhibitors of USP1 target ID1 degradation in leukemic cells.

Mistry H, Hsieh G, Buhrlage SJ, Huang M, Park E, Cuny GD, Galinsky I, Stone RM, Gray NS, D'Andrea AD, Parmar K.

Mol Cancer Ther. 2013 Dec;12(12):2651-62. doi: 10.1158/1535-7163.MCT-13-0103-T. Epub 2013 Oct 15.

7.

Peptide-mediated Cell and In Vivo Delivery of Antisense Oligonucleotides and siRNA.

Järver P, Coursindel T, Andaloussi SE, Godfrey C, Wood MJ, Gait MJ.

Mol Ther Nucleic Acids. 2012 Jun 12;1:e27. doi: 10.1038/mtna.2012.18. No abstract available.

8.

Targeted tumor-penetrating siRNA nanocomplexes for credentialing the ovarian cancer oncogene ID4.

Ren Y, Cheung HW, von Maltzhan G, Agrawal A, Cowley GS, Weir BA, Boehm JS, Tamayo P, Karst AM, Liu JF, Hirsch MS, Mesirov JP, Drapkin R, Root DE, Lo J, Fogal V, Ruoslahti E, Hahn WC, Bhatia SN.

Sci Transl Med. 2012 Aug 15;4(147):147ra112. doi: 10.1126/scitranslmed.3003778.

9.

A new module in neural differentiation control: two microRNAs upregulated by retinoic acid, miR-9 and -103, target the differentiation inhibitor ID2.

Annibali D, Gioia U, Savino M, Laneve P, Caffarelli E, Nasi S.

PLoS One. 2012;7(7):e40269. doi: 10.1371/journal.pone.0040269. Epub 2012 Jul 25.

10.

111In-BnDTPA-F3: an Auger electron-emitting radiotherapeutic agent that targets nucleolin.

Cornelissen B, Waller A, Target C, Kersemans V, Smart S, Vallis KA.

EJNMMI Res. 2012 Feb 20;2:9. doi: 10.1186/2191-219X-2-9.

11.

Inhibitor of differentiation-3 mediates high fat diet-induced visceral fat expansion.

Cutchins A, Harmon DB, Kirby JL, Doran AC, Oldham SN, Skaflen M, Klibanov AL, Meller N, Keller SR, Garmey J, McNamara CA.

Arterioscler Thromb Vasc Biol. 2012 Feb;32(2):317-24. doi: 10.1161/ATVBAHA.111.234856. Epub 2011 Nov 10.

12.

Induction of antagonistic soluble decoy receptor tyrosine kinases by intronic polyA activation.

Vorlová S, Rocco G, Lefave CV, Jodelka FM, Hess K, Hastings ML, Henke E, Cartegni L.

Mol Cell. 2011 Sep 16;43(6):927-39. doi: 10.1016/j.molcel.2011.08.009.

13.

ID family protein expression and regulation in hypoxic pulmonary hypertension.

Lowery JW, Frump AL, Anderson L, DiCarlo GE, Jones MT, de Caestecker MP.

Am J Physiol Regul Integr Comp Physiol. 2010 Dec;299(6):R1463-77. doi: 10.1152/ajpregu.00866.2009. Epub 2010 Sep 29.

14.

Inhibition of Id proteins by a peptide aptamer induces cell-cycle arrest and apoptosis in ovarian cancer cells.

Mern DS, Hasskarl J, Burwinkel B.

Br J Cancer. 2010 Oct 12;103(8):1237-44. doi: 10.1038/sj.bjc.6605897. Epub 2010 Sep 14.

15.

WSS25 inhibits growth of xenografted hepatocellular cancer cells in nude mice by disrupting angiogenesis via blocking bone morphogenetic protein (BMP)/Smad/Id1 signaling.

Qiu H, Yang B, Pei ZC, Zhang Z, Ding K.

J Biol Chem. 2010 Oct 15;285(42):32638-46. doi: 10.1074/jbc.M110.105544. Epub 2010 Aug 2.

16.

Targeting of drugs and nanoparticles to tumors.

Ruoslahti E, Bhatia SN, Sailor MJ.

J Cell Biol. 2010 Mar 22;188(6):759-68. doi: 10.1083/jcb.200910104. Epub 2010 Mar 15. Review.

17.

KLF17 is a negative regulator of epithelial-mesenchymal transition and metastasis in breast cancer.

Gumireddy K, Li A, Gimotty PA, Klein-Szanto AJ, Showe LC, Katsaros D, Coukos G, Zhang L, Huang Q.

Nat Cell Biol. 2009 Nov;11(11):1297-304. doi: 10.1038/ncb1974. Epub 2009 Oct 4.

18.

Bone marrow-derived endothelial progenitor cells contribute to the angiogenic switch in tumor growth and metastatic progression.

Gao D, Nolan D, McDonnell K, Vahdat L, Benezra R, Altorki N, Mittal V.

Biochim Biophys Acta. 2009 Aug;1796(1):33-40. doi: 10.1016/j.bbcan.2009.05.001. Epub 2009 May 19. Review.

19.

RNAi-mediated c-Rel silencing leads to apoptosis of B cell tumor cells and suppresses antigenic immune response in vivo.

Tian W, Liou HC.

PLoS One. 2009;4(4):e5028. doi: 10.1371/journal.pone.0005028. Epub 2009 Apr 6.

20.

Systematic surface engineering of magnetic nanoworms for in vivo tumor targeting.

Park JH, von Maltzahn G, Zhang L, Derfus AM, Simberg D, Harris TJ, Ruoslahti E, Bhatia SN, Sailor MJ.

Small. 2009 Mar;5(6):694-700. doi: 10.1002/smll.200801789.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk